Lenz & Staehelin advised Chord Therapeutics in its Series A financing

Chord Therapeutics, a Geneva clinical stage biopharmaceutical company developing drugs for rare diseases, announced the closing of a USD 16 million Series A financing from leading healthcare investor Omega Funds. The financing will allow the company to progress its lead drug candidate, CRD1, a small molecule oral drug for the treatment of neuromyelitis optica spectrum disorders, through Phase 2 proof of concept clinical development.

 

The team

Lenz & Staehelin advised Chord Therapeutics in its Series A financing. The team was led by Guy Vermeil (pictured) and included David Ledermann and Federico Trabaldo Togna (all Corporate, M&A), Floran Ponce (Tax), Sevan Antreasyan (Intellectual Property) and Prisca Cattaneo (Employment).

Lenz & Staehelin advised Chord Therapeutics in its Series A financing

FabioAdmin

Legalcommunity.ch

Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio

SHARE

Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram